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Background

Results

Patients with head and neck cancer (HNC) undergoing
radiotherapy (RT) may experience chronic side effects, such as
xerostomia and dysphagia, which can have a severe negative
impact on quality of life (QoL)1. Predicting these symptoms in
HNC patients is thus of clinical interest, and recent quantitative
approaches have provided insight into these symptom
trajectories.

So far, correlations between acute and
late AUCs have been initially calculated.
At this early stage, acute AUC s does
appear to be significantly correlated with
late AUCs for several locoregional
symptoms, most notably dry mouth
(Spearman’s rho 0.47, p < 0.0001) and
taste (Spearman’s rho 0.40, p <0.0001)
(Fig 3). The relationships between acute
and late AUCs were also graphed as
scatter plots and linear regressions were
calculated; the plot for dry mouth is
shown below (R2 = 0.24, Fig 4).The next
steps are to calculate composite
interference scores, to calculate
correlations between these scores and
acute/late symptom AUCs, and finally to
assess the effects of treatment, staging,
age, and gender on these relationships.

Our lab recently developed a measure of symptom burden over
time, the area under the symptom trajectory curve (AUCsymptom or
AUCs), which condenses symptom data over the course of
treatment and beyond into a single data point while maintaining
its temporal nature (Fig 1)2. Previous studies have indicated that
acute symptoms, particularly xerostomia and dysphagia, strongly
predict late symptoms3, but this relationship for the AUCs has not
been established. Further, the ability of the AUC s to identify the
impacts of specific symptoms on QoL is currently unknown.
Consequently, our objectives for this study are to expand upon
our lab’s previous work to determine the predictive value of the
acute AUCs for late AUCs and to use AUCs data to identify
symptoms associated with lower patient-reported QoL.

Figure 3 (right): Heatmap of Spearman’s rho
correlations between acute AUC s and late AUCs
for each item on the MDASI-HN. P-values <
0.0001 are reported as extremely significant (****).

Figure 1. Sample illustration of the area under the symptom trajectory curve
(AUCsymptom) for several symptom trajectories, adapted from Van Dijk et al.2
The AUCsymptom represents the percentage of area covered by the symptom
score for a specific interval divided by the maximum potential area.

Methods
AUCs data from 336 patients from a registry at MD Anderson
Cancer Center of patients evaluated for a suspected or
confirmed diagnosis of oropharyngeal cancer (OPC),
previously calculated by our lab2, was used in the present
study. AUCs data were originally derived from patient
responses to the MDASI-HN, a validated, head and neck
specific, 28-item symptom reporting tool in which patients rate
symptoms from 0 (none) to 10 (worst imaginable). MDASI
items are split into core symptoms and interference items,
which patients use to rate the severity of their symptoms and
estimate how much their symptoms interfere with normal life
activities (Fig 2).

Discussion
Symptom

Spearman's rho

p-value

n

dry mouth

0.4708

****

314

taste

0.4009

****

312

mucus

0.3203

****

301

fatigue

0.3142

****

287

drowsy

0.3114

****

245

swallow

0.2922

****

289

appetite

0.2693

****

280

pain

0.2544

****

291

mucositis

0.2417

****

262

sad

0.2191

0.0254*

104

activity

0.1909

0.0041** 224

sleep

0.1804

0.0042** 250

nausea

0.1618

0.0378* 165

enjoy

0.1486

0.0348*

202

work

0.1394

0.0402*

217

skin

0.1213

0.0825

206

constipation

0.1063

0.1566

179

distress

0.08211

0.3245

146

relations

0.05389

0.5332

136

mood

0.04811

0.5213

180

vomit

0.03714

0.7534

74

voice

0.02067

0.7824

181

walking

0.009144

0.9197

124

choke

0.0009205

0.9906

167

sob

-0.02445

0.8373

73

memory

-0.0311

0.7213

134

numb

-0.09869

0.3547

90

teeth

-0.144

0.0711

158

Figure 2. Sample form depicting core and interference items for
the M.D. Anderson Symptom Inventory (MDASI).5

Conclusions
While it is premature to draw strong conclusions from
our work so far, we anticipate that this project will
demonstrate the validity of the AUCsymptom measure
and encourage further study of its potential for
understanding treatment side effects that are most
important to HNC patients. With further validation,
AUCsymptom may present an opportunity for clinicians to
utilize data-driven or algorithmic approaches to provide
individualized care proactively rather than reactively. In
addition, while this measure was developed for HNC
patients, it could easily be adapted for other cancers,
and could be used to monitor and prevent any number
of treatment side effects, especially those with wellknown trajectories. Perhaps the AUCsymptom may one
day become an integral part of the clinician’s toolbox in
delivering individually personalized, highly effective
cancer treatment.
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Figure 3. Scatter plot and linear regression of acute AUCs for a single
symptom (dry mouth) vs. late AUCs for dry mouth. AUCs values are reported
as percentages.
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